BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease

Stockholm, May 6, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson's disease. The patent will take effect on May 24, 2022, and expire in 2041, with the possibility of a patent term extension up until 2046.

The release as fetched from its publisher. bioarctic.com ↗